Vertex Pharmaceuticals Stock Plummets -7.3% With 5-Day Losing Streak
Vertex Pharmaceuticals (VRTX) – a developer of cystic fibrosis therapies and treatments – hit a 5-day losing streak, with cumulative losses over this period amounting to -7.3%. The company’s market cap has crashed by about $9.3 Bil over the last 5 days and currently stands at $117 billion.
Is this an opportunity or a trap? There is not much to fear in VRTX stock given its overall Strong operating performance and financial condition. This is aligned with the stock’s High valuation because of which we think it is Fairly Priced (For details, see Buy or Sell VRTX).
But here is the interesting part. You are reading about this -7.3% move after it happened. The market has already priced in the news. To manage individual stock risk before the headlines, you need predictive signals, not notifications. High Quality Portfolio has a risk model designed to manage stock-specific drawdowns better.
Returns vs S&P 500
- Wheaton’s Pullback: Temporary Noise or Real Opportunity?
- Get Paid 9.8% to Buy CRM at a 30% Discount – Here’s How
- The Credibility Gap: Why Carvana’s Best Quarter In Years Led To Its Steepest Sell-Off
- Adobe Stock: Strong Cash Flow Poised for a Re-Rating?
- Microsoft Stock Pays Out $376 Bil – Investors Take Note
- Apple Stock Hands $874 Bil Back – Worth a Look?
The following table summarizes the return for VRTX stock vs. the S&P 500 index over different periods, including the current streak:
| Return Period | VRTX | S&P 500 |
|---|---|---|
| 1D | -0.8% | 0.2% |
| 5D (Current Streak) | -7.3% | -1.0% |
| 1M (21D) | -5.9% | -1.8% |
| 3M (63D) | 2.3% | -1.6% |
| YTD 2026 | 2.0% | -1.9% |
| 2025 | 12.6% | 16.4% |
| 2024 | -1.0% | 23.3% |
| 2023 | 40.9% | 24.2% |
Take a look at what history tells you about whether past dips like this have been buying opportunities or traps: VRTX Dip Buyer Analysis.
Gains and Losses Streaks: S&P 500 Constituents
There are currently 117 S&P constituents with 3 days or more of consecutive gains and 18 constituents with 3 days or more of consecutive losses.
| Consecutive Days | # of Gainers | # of Losers |
|---|---|---|
| 3D | 102 | 5 |
| 4D | 10 | 6 |
| 5D | 5 | 4 |
| 6D | 0 | 1 |
| 7D or more | 0 | 2 |
| Total >=3 D | 117 | 18 |
Key Financials for Vertex Pharmaceuticals (VRTX)
Last 2 Fiscal Years:
| Metric | FY2024 | FY2025 |
|---|---|---|
| Revenues | $11.0 Bil | $12.0 Bil |
| Operating Income | $-233.4 Mil | $4.6 Bil |
| Net Income | $-535.6 Mil | $4.0 Bil |
Last 2 Fiscal Quarters:
| Metric | 2025 FQ3 | 2025 FQ4 |
|---|---|---|
| Revenues | $3.1 Bil | $3.2 Bil |
| Operating Income | $1.2 Bil | $1.1 Bil |
| Net Income | $1.1 Bil | $1.2 Bil |
The losing streak VRTX stock is currently on doesn’t inspire much confidence among investors. In contrast, Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 — the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.